Pharmaceuticals
News Category
NanoViricides Raises $3.8 Million in Registered Direct Offering to Advance Antiviral Drug Pipeline
NanoViricides announced a $3.8 million registered direct offering with a single institutional investor, providing capital to support clinical developm...
VERAXA Biotech Appoints Christoph Erkel as Chief Scientific Officer to Advance BiTAC Platform
VERAXA Biotech AG announced the appointment of Christoph Erkel as chief scientific officer, bringing two decades of antibody engineering experience to...
VERAXA Biotech Advances BiTAC(R)-TCE Development with Positive Regulatory Feedback from Germany
VERAXA Biotech AG received Scientific Advice from Germany's Paul-Ehrlich-Institute, supporting its lead BiTAC(R)-TCE program's development strategy an...
VERAXA Biotech Receives Regulatory Feedback for BiTAC-TCE Cancer Therapy Platform
VERAXA Biotech AG announced positive regulatory feedback from Germany's Paul-Ehrlich-Institute for its BiTAC-TCE platform, advancing the program towar...
Siegfried Appoints Eduardo Montanha as Chief Operating Officer to Drive Integrated Operations
Siegfried has appointed Eduardo Montanha as COO and Executive Committee member, effective September 1, 2026, to oversee the combined Drug Substances a...
NextPlat Corp Expands PharmcoRx With Planned Florida Pharmacy Acquisition
NextPlat Corp acquires an independent pharmacy near Pensacola, Florida for $1.5 million to expand its PharmcoRx retail footprint into an underserved m...
Onco-Innovations Completes Analytical Reference Standard for Lead Oncology Candidate ONC010
Onco-Innovations announced the completion of its analytical reference standard program for the active pharmaceutical ingredient supporting ONC010, a k...
VERAXA Biotech Advances Lead BiTAC T-Cell Engager Program with Cell Line Development Partnership
VERAXA Biotech has partnered with ATUM to initiate cell line development for its lead BiTAC T-cell engager, a key step toward IND/CTA-enabling studies...
Sustained Release Polymers Market Set to Reach USD 7.8 Billion by 2036, Driven by Chronic Disease Management and Advanced Drug Delivery
The sustained release polymers market is projected to grow from USD 3.8 billion in 2026 to USD 7.8 billion by 2036 at a CAGR of 7.4%, driven by rising...
VERAXA Biotech Advances BiTAC Pipeline and Partnering Strategy in First Half of 2026
VERAXA Biotech AG provided a corporate update highlighting progress in its proprietary BiTAC platform, with four T-cell engager programs targeting sol...
VERAXA Biotech Initiates Cell Line Development for Lead BiTAC Cancer Therapy Program
VERAXA Biotech has begun cell line development for its lead BiTAC T-cell engager therapy, aiming to improve tumor selectivity and reduce off-tumor tox...
VERAXA Biotech AG: Why Antibody Therapeutics Sector Deals Signal Value for Shareholders
The article highlights how strategic partnerships and licensing deals in antibody-drug conjugates (ADCs) and T-cell engagers (TCEs) are creating value...
Ace Therapeutics Launches Comprehensive Preclinical Analgesic Drug Development Services
Ace Therapeutics announces end-to-end preclinical analgesic drug development services featuring a full-spectrum pain research platform with diverse in...
Medios AG Closes Aschaffenburg Facility to Optimize Manufacturing Network
Medios AG is closing its Aschaffenburg facility to consolidate patient-specific manufacturing amid margin pressure from price regulations, affecting 3...
Helus Pharma Reports Fiscal 2026 Results, Phase 3 Trial for Depression Drug Nears Completion
Helus Pharma announced fiscal 2026 financial results and progress on its Phase 3 trial for HLP003, a major depressive disorder treatment, with topline...
Voyageur Pharmaceuticals Engages Fluor for Feasibility Studies on Iodine Production and Integrated Contrast Drug Facility
Voyageur Pharmaceuticals has hired Fluor to conduct feasibility studies for an iodine extraction facility in Oklahoma and an integrated contrast drug ...
Knight Therapeutics Repays $60 Million Credit Facility Used for Paladin Acquisition
Knight Therapeutics has fully repaid its $60 million revolving credit facility drawn to finance the Paladin acquisition, using strong operational cash...
Voyageur Pharmaceuticals Evaluates Three U.S. Sites for Integrated Iodine and Barium Contrast Media Manufacturing Facility
Voyageur Pharmaceuticals is evaluating three potential U.S. sites for its integrated iodine and barium contrast media manufacturing facility, aiming t...
Earth Science Tech Inc. (ETST) Positions Itself at the Intersection of Telemedicine, Pharmacy, and Healthcare Services
Earth Science Tech Inc. (ETST) has transformed into a diversified holding company with a vertically integrated telehealth and pharmacy ecosystem, emph...
Voyageur Pharmaceuticals Submits Multi-Year Permit Application for Frances Creek Barite Project, Advancing Toward Feasibility Study
Voyageur Pharmaceuticals has submitted a multi-year area-based exploration permit application for its Frances Creek barite project in British Columbia...
Voyageur Closes $5 Million Private Placement for Barium Contrast Product Development
Voyageur Pharmaceuticals closed a $5 million private placement to fund FDA licensing for its barium contrast products and other projects, marking a ke...
Kairos Pharma Announces Pipeline Expansion and Clinical Milestones in Mid-Year Update
Kairos Pharma's mid-year 2026 update highlights plans to acquire Phase 1-ready CL-741 for EGFR-mutated lung cancer, advance ENV-105 trials, and secure...
Quantum BioPharma Highlights Lucid-MS and unbuzzd Growth Opportunities on BioMedWire Podcast
Quantum BioPharma's lead drug candidate Lucid-MS targets mobility loss in multiple sclerosis by addressing nerve damage, a currently unmet need, while...
Quantum BioPharma Ltd. Advances Multiple Sclerosis Program with Differentiated Approach
Quantum BioPharma is progressing a clinical-stage multiple sclerosis program targeting demyelination, with Phase 1 safety studies completed and a plan...
Redwood AI Corp. Achieves DTC Eligibility and Engages IBN for Investor Awareness
Redwood AI Corp. announced DTC eligibility for its common shares, simplifying U.S. trading and enhancing liquidity, and engaged InvestorBrandNetwork f...
Carmed Pharmaceuticals Gains CityBiz Spotlight as U.S. Market Expansion Accelerates
Carmed Pharmaceuticals, a Turkey-based company specializing in standardized carvacrol formulations, is highlighted in a CityBiz feature as it expands ...
Sino Biological Launches XPressMAX™ Cell-Free Protein Synthesis Kit to Accelerate AI-Powered Antibody Discovery
Sino Biological's new XPressMAX™ kit enables rapid, high-throughput cell-free protein synthesis in 3 hours, supporting AI-driven antibody drug discove...
NanoViricides Advances NV-387 Toward Phase II Trials for MPox and Other Viral Targets
NanoViricides reported progress on its broad-spectrum antiviral NV-387, including regulatory approval for Phase II MPox trials in the DRC and FDA orph...
NanoViricides Prices $2 Million Registered Direct Offering to Fund Antiviral Development
NanoViricides announced a $2 million registered direct offering with a single institutional investor, highlighting continued support for its broad-spe...
Lantern Pharma Closes $4.4 Million Registered Direct Offering to Fund AI-Driven Precision Oncology Pipeline
Lantern Pharma raised $4.4 million through a registered direct offering, with potential for additional $4.85 million from warrants, to support its AI-...
Tonix Pharmaceuticals to Present at Two Major Investor Conferences in May
Tonix Pharmaceuticals (NASDAQ: TNXP) will showcase its CNS and immunology pipeline at the RBC Capital Markets Global Healthcare Conference and A.G.P.’...
Lantern Pharma Expands predictBBB Platform into Large Quantitative Model for Drug Discovery
Lantern Pharma has enhanced its predictBBB platform into a Large Quantitative Model, offering real-time molecular intelligence to accelerate drug disc...
LIXTE Biotechnology’s LB-100 Aims to Enhance Cancer Treatment Efficacy Through PP2A Inhibition
LIXTE Biotechnology’s LB-100, a first-in-class PP2A inhibitor, is being evaluated in clinical trials to boost the effectiveness of existing cancer the...
Soligenix Leverages Synthetic Hypericin Platform to Target Multiple Dermatologic Indications
Soligenix's use of synthetic hypericin across two distinct dermatologic indications exemplifies platform-based drug development, which streamlines pre...
PolyPeptide Shareholders Approve All Board Proposals at 2026 Annual General Meeting
PolyPeptide Group AG announced that shareholders approved all board proposals at the 2026 Annual General Meeting, including re-election of directors a...
LIXTE Biotechnology Holdings Files 2025 Form 10-K, Highlights Transformational Year with Clinical and Strategic Advances
LIXTE Biotechnology Holdings filed its 2025 Form 10-K, detailing clinical progress for LB-100, the acquisition of Liora Technologies Europe Ltd., and ...
LIXTE Biotechnology's PP2A Inhibitor LB-100: A Potential Game-Changer in Cancer Treatment
LIXTE Biotechnology holds the world's only clinical-stage PP2A inhibitor, LB-100, which enhances cancer cell sensitivity to therapy and disrupts repai...
Lonza Nominates Stephen Fry for Board of Directors
Lonza nominates former Eli Lilly executive Stephen Fry as an independent board member, leveraging his expertise in pharma industry transformation and ...
Voyageur Pharmaceuticals Advances Barium and Iodine Contrast Media Projects with Strategic Roadmap
Voyageur Pharmaceuticals provides a corporate update on its vertically integrated barium and iodine contrast media projects, including feasibility stu...
Soligenix Secures Key European Milestone for Dusquetide Development
Soligenix receives positive EMA opinion for orphan drug designation of dusquetide in Behçet's disease, unlocking incentives that could accelerate deve...
NETHERTON NOW Campaign Surpasses 2 Million Video Views, Amplifying Voices of Netherton Syndrome Community on Rare Disease Day
Quoin Pharmaceuticals' NETHERTON NOW awareness campaign has achieved 2 million video views and 24 million impressions, highlighting the growing global...
Why Late-Stage CNS, Oncology Assets Are Becoming the Hottest Targets in Biotech M&A
Oncotelic Therapeutics is highlighted in a BioMedWire editorial examining the growing trend of biotech M&A focusing on de-risked, late-stage assets wi...
Helus Pharma Phase 2a SPL026 Data Published in Nature Medicine Shows Significant Reduction in Depressive Symptoms
Helus Pharma announced publication in Nature Medicine of Phase 2a trial results showing a single dose of SPL026 achieved statistically significant and...